Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
Novo Nordisk (NVO) reported Q2 2026 sales up 3% to $12.21B (CER), but Ozempic and Wegovy sales were flat at CER. Ozempic was $4.88B and Wegovy $3.03B. Eli Lilly (LLY) posted Mounjaro $9.9B (+91%) and Zepbound $4.9B (+46%). NVO raised 2026 guidance; it also sued Lilly. Oral GLP-1s: Wegovy pill $0.50B, Ozempic pill $0.81B; Lilly’s orforglipron $98M.
How this was made
The 30-second read
Why it matters
For NVO, the key trade is whether oral growth can offset slowing injectable sales and a guidance reset. For LLY, the key trade is whether continued injectable momentum plus an oral obesity pill sustains share gains and limits NVO’s ability to re-accelerate.
Market read
Traders get a same-article mix of Q2 performance, guidance change, and competitive product developments (oral GLP-1 and litigation), which can drive relative positioning between NVO and LLY.
What to watch
The article does not quantify pricing changes, market share metrics, or the magnitude/timing of NVO’s legal impact on Lilly advertising, which could alter near-term sentiment.
Background
The piece frames the GLP-1 market as shifting from injectable dominance toward oral options, with NVO defending its franchise against LLY’s expanding pipeline and share gains.
Ticker impact
Novo Nordisk reported Q2 2026 sales up 3% but Ozempic and Wegovy sales were flat at CER, signaling slowing GLP-1 momentum.
Bias to downside or underperformance versus LLY until oral growth offsets injectable deceleration.
The article cites flat Ozempic and Wegovy at CER, a competitive threat from Lilly’s oral pill, and a guidance reset to a smaller decline range.
Eli Lilly posted Q2 GLP-1 growth with Mounjaro up 91% and Zepbound up 46%, and it launched Foundayo (orforglipron) with early sales.
Bias to relative strength as traders price continued share capture in both injectables and oral obesity.
The article provides large YoY growth rates for Mounjaro and Zepbound and notes Foundayo’s launch plus an FDA T2D application.
Market effects
Reinforces a GLP-1 competitive regime where oral formulations can shift share dynamics, pressuring incumbents’ growth rates.
US-focused oral availability details (Ozempic pill nationwide in May) keep attention on US demand and label expansion.
Competition narrative is global across diabetes and obesity markets, affecting broader GLP-1 supply chain and pricing expectations.
Counterpoint
NVO’s oral GLP-1 prescription ramp could accelerate later, and flat CER growth may reflect mix or timing rather than durable share loss.
Key entities
- companyNovo Nordisk
GLP-1 franchise holder (Ozempic, Wegovy) reporting Q2 slowing injectable growth, oral pill traction, and guidance trimming.
- companyEli Lilly
GLP-1 growth leader (Mounjaro, Zepbound) and oral obesity entrant Foundayo, with FDA application for T2D.
- companyViking Therapeutics
Developing VK2735 for obesity, including planned oral phase III advancement.
- companyStructure Therapeutics
Advancing orally administered aleniglipron in late-stage obesity program after phase II weight-loss results.
